Merck & Co., Inc. (TSX:MRK)

Market Cap	381.22B
Revenue (ttm)	89.47B
Net Income (ttm)	26.51B
Shares Out	n/a
EPS (ttm)	10.52
PE Ratio	14.38
Forward PE	12.08
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,891
Average Volume	5,379
Open	24.80
Previous Close	25.17
Day's Range	24.60 - 24.80
52-Week Range	16.84 - 25.34
Beta	n/a
RSI	63.85
Earnings Date	Feb 3, 2026

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1891
• Employees: 75,000
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: MRK

Financial Performance

In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.

Financial numbers in USD